<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353742</url>
  </required_header>
  <id_info>
    <org_study_id>114957</org_study_id>
    <nct_id>NCT01353742</nct_id>
  </id_info>
  <brief_title>Lamivudine and Adefovir Dipivoxil Fixed Dose Combination</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study being conducted to support the clinical development program of a FDC&#xD;
      product of the nucleoside analogue lamivudine and the nucleotide analogue adefovir dipivoxil.&#xD;
      To establish bioequivalence, the exposure of lamivudine and adefovir dipivoxil when&#xD;
      administered as the FDC will be compared to that of Heptodin (lamivudine) and Hepsera&#xD;
      (adefovir dipivoxil) when administered separately. In this study, the FDC product will&#xD;
      contain 100mg lamivudine/10mg adefovir dipivoxil.&#xD;
&#xD;
      Total 40 healthy adult subjects will be enrolled. The study will include a screening visit&#xD;
      and two treatment sessions. The screening visit will be conducted up to 3 weeks prior to the&#xD;
      first dose of Session 1. All subjects will receive Regimen A through B according to the&#xD;
      randomization schedule. Eligible subjects will be enrolled in the study and randomized to&#xD;
      receive the following treatment regimens in table below in one of the following treatment&#xD;
      sequences: AB, or BA. There will be a seven to ten days washout period between each treatment&#xD;
      session. Pharmacokinetic sampling for measurement of plasma lamivudine and adefovir dipivoxil&#xD;
      concentrations will be conducted over a 48-hour period following the morning administration&#xD;
      of study medication in each study session. During this time, all subjects will remain in the&#xD;
      unit for pharmacokinetic (PK) sample collection. The total duration (from screening to the&#xD;
      end of the study) of each subject's participation will be approximately four weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) infection is common, with an estimated global prevalence of more&#xD;
      than 400 million people, or approximately 5% of the world's population. Chronic hepatitis B&#xD;
      virus (HBV) carriers with evidence of ongoing viral replication are at highest risk for the&#xD;
      development of active liver inflammation (i.e., hepatitis B) and progressive liver disease.&#xD;
      They are also the major contributor to the spread of HBV infection.&#xD;
&#xD;
      The goals of therapy in CHB include suppression of HBV replication, reduction of&#xD;
      necroinflammatory processes in the liver, and prevention of progression to serious liver&#xD;
      disease or death. The HBV polymerase has an error rate that is intermediate between that of&#xD;
      human immunodeficiency virus (HIV) and herpes virus polymerases,; this predicts that patients&#xD;
      with CHB infection are likely to exhibit some degree of antiviral resistance to nucleoside or&#xD;
      nucleotide monotherapies. Indeed, patients on long-term lamivudine therapy have been found to&#xD;
      have HBV variants (YMDD variants) with reduced sensitivity to lamivudine in vitro, and have&#xD;
      exhibited variably diminished therapeutic responses.&#xD;
&#xD;
      A fixed dose combination (FDC) formulation of lamivudine and adefovir dipivoxil for the&#xD;
      treatment of CHB. Lamivudine (Heptodin) an active triphosphate (3TC-TP) incorporating into&#xD;
      growing DNA chains results in premature chain termination thereby inhibiting HBV DNA&#xD;
      synthesis. Adefovir dipivoxil (Hepsera) is an orally bioavailable pro-drug of adefovir, a&#xD;
      nucleotide analog of adenosine monophosphate. It can inhibit both the reverse transcriptase&#xD;
      and DNA polymerase activity and is incorporated into HBV DNA causing chain termination.&#xD;
&#xD;
      A FDC would therefore combine the established benefits of two important anti-HBV antiviral&#xD;
      drugs, representing the first combination product for the treatment of CHB. In addition to&#xD;
      the enhanced efficacy afforded by combination therapy, the use of a combination product could&#xD;
      enhance convenience and compliance and ensure that patients receive the two drugs needed.&#xD;
&#xD;
      This study will evaluate the bioequivalence of a FDC containing (lamivudine 100 mg/adefovir&#xD;
      dipivoxil 10 mg) compared to Heptodin100 mg and Hepsera 10 mg. This dose was selected as both&#xD;
      Heptodin 100 mg and Hepsera 10 mg are approved in the PRC for the treatment of CHB. Based on&#xD;
      extensive clinical experience with the use of both drugs either as monotherapy or in&#xD;
      combination, it is anticipated that the co-administration of both agents in the FDC&#xD;
      formulation will be well-tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2011</start_date>
  <completion_date type="Actual">April 12, 2011</completion_date>
  <primary_completion_date type="Actual">April 12, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of lamivudine</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of lamivudine</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of adefovir dipivoxil</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of adefovir dipivoxil</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters: t1/2 of lamivudine</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability will be assessed by clinical data from Adverse Event reporting, nurse/physician observations, vital signs, ECGs, and clinical laboratory.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Tmax of lamivudine</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Tmax of adefovir dipivoxil</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: t1/2 of adefovir dipivoxil</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Lamivudine and Adefovir dipivoxil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule (100mg lamivudine and 10mg adefovir dipivoxil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>100mg tablet</description>
    <arm_group_label>Lamivudine and Adefovir dipivoxil</arm_group_label>
    <other_name>Heptodin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>10mg tablet</description>
    <arm_group_label>Lamivudine and Adefovir dipivoxil</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose combination (Lamivudine and Adefovir dipivoxil)</intervention_name>
    <description>100mg/10mg capsule</description>
    <arm_group_label>Fixed dose combination</arm_group_label>
    <other_name>FDC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible physician.&#xD;
&#xD;
          -  Male 18 and 55 years of age.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods.&#xD;
&#xD;
          -  Body weight &gt;50 kg (110 lbs) and body mass index (BMI) between 19.0 and 25.0.&#xD;
&#xD;
          -  Capable of giving written informed consent.&#xD;
&#xD;
          -  QT interval corrected according to Bazzett's formula (QTcB) or QT interval corrected&#xD;
             according to Fridericia's formula (QTcF) &lt;450 msec; or QTc &lt;480 msec in subjects with&#xD;
             Bundle Branch Block.&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin &lt;=1.5xULN (isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality identified on the screening history, physical or&#xD;
             laboratory examination, or any other medical condition or circumstance making the&#xD;
             subject unsuitable for participation in the study.&#xD;
&#xD;
          -  Treatment with any prescription or non-prescription drugs (including vitamins, herbal&#xD;
             and dietary supplements, as well as grapefruit-containing products) within 7 days or&#xD;
             five half-lives prior to first dose of study medication and until the end of the&#xD;
             study. Excluded from this list is acetaminophen at doses of &lt;=2 grams/day.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days or five half-lives (whichever is&#xD;
             longer) preceding Day 1 of treatment period 1.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 7 drinks/week for women or 14&#xD;
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of&#xD;
             hard liquor) within 6 months of screening.&#xD;
&#xD;
          -  Positive urine drug screen (UDS) or breath alcohol test at screening. A minimum list&#xD;
             of drugs that will be screened for include amphetamines, barbiturates, cocaine,&#xD;
             opiates, cannabinoids and benzodiazepines.&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C or HIV.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Electrocardiogram findings as follows (a single repeat is allowed for eligibility&#xD;
             determination):&#xD;
&#xD;
        Parameter Males Heart rate &lt;45 and &gt;100 beats per minute PR Interval &lt;120 and &gt;220 msec QRS&#xD;
        duration &lt;70 and &gt;120 msec QTc interval (Bazett) &gt;450 msec&#xD;
&#xD;
          -  Evidence of previous myocardial infarction (does not include ST segment changes&#xD;
             associated with repolarization).&#xD;
&#xD;
          -  Any conduction abnormality (including but not specific to left or right complete&#xD;
             bundle branch block, atrio-ventricular block [second degree or higher], Wolf Parkinson&#xD;
             White syndrome).&#xD;
&#xD;
          -  Sinus pauses &gt;3 seconds.&#xD;
&#xD;
          -  Any significant arrhythmia which, in the opinion of the principal Investigator and&#xD;
             GlaxoSmithKline medical monitor, will interfere with the safety for the individual&#xD;
             subject.&#xD;
&#xD;
          -  Non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular&#xD;
             ectopic beats).&#xD;
&#xD;
               -  Documented history of low blood pressure (BP; average systolic BP&lt;=90 mmHg and/or&#xD;
                  diastolic BP &lt;=45 mm Hg) or blood pressure below these values at time of&#xD;
                  screening.&#xD;
&#xD;
               -  Where participation in the study would result in donation of blood or blood&#xD;
                  products in excess of 500 mL within a 56 day period.&#xD;
&#xD;
               -  History of asthma or chronic obstructive pulmonary disease.&#xD;
&#xD;
               -  History of sensitivity to heparin, heparin- induced thrombocytopenia, or&#xD;
                  sensitivity to any of the study medications or components thereof.&#xD;
&#xD;
               -  History of anaphylaxis or anaphylactic reactions or severe allergic responses to&#xD;
                  drugs.&#xD;
&#xD;
               -  History of angioedema.&#xD;
&#xD;
               -  Unwillingness or inability to follow the procedures outlined in the protocol or&#xD;
                  inability to provide written informed consent.&#xD;
&#xD;
               -  Subject is mentally or legally incapacitated&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan;35(1):68-76. doi: 10.1016/j.clinthera.2012.12.001. Epub 2012 Dec 28.</citation>
    <PMID>23274144</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114957</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

